BioCentury
ARTICLE | Company News

SuperGen, Abbott deal

January 4, 2000 8:00 AM UTC

ABT will exclusively market worldwide SUPG's rubitecan (RFS 2000) oral chemotherapy compound, which is in Phase III testing to treat pancreatic cancer (see BioCentury Extra, Dec. 23, 1999). The compan...